Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | ALDH3A1 | P30838 | 7/20 | 0.71 |
| ▸ | ALDH2 | P05091 | 5/20 | 0.71 |
| ▸ | ACHE | P22303 | 3/20 | 0.66 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9904848 | 0.86 | ALDH3A1 (0.72) | ALDH1A1ALDH3A1ALDH2CHRM5CES1 | |
| SCHEMBL5659656 | 0.84 | ACHE (0.66) | ALDH1A1ALDH3A1ALDH2ACHECHRM5 | |
| SCHEMBL5657440 | 0.84 | ALDH1A1 (0.67) | ALDH1A1ALDH3A1ALDH2ACHECHRM5 | |
| SCHEMBL15094362 | 0.84 | CHRM5 (0.66) | ALDH1A1ALDH3A1ALDH2ACHECHRM5 | |
| SCHEMBL5659265 | 0.83 | ALDH1A1 (1.00) | ALDH1A1ALDH3A1ALDH2ACHECHRM5 | |
| SCHEMBL4609842 | 0.83 | CES1 (0.66) | ALDH1A1ALDH3A1ALDH2ACHECHRM5 | |
| SCHEMBL18954751 | 0.82 | ALDH1A1 (0.67) | ALDH1A1ALDH3A1ALDH2ACHECHRM5 | |
| SCHEMBL18954802 | 0.81 | CHRM5 (0.60) | ALDH1A1ALDH3A1ALDH2ACHECHRM5 | |
| SCHEMBL14740713 | 0.81 | CHRM5 (0.73) | ALDH1A1ALDH3A1ALDH2CHRM5CA12 | |
| SCHEMBL28053294 | 0.80 | ACHE (1.00) | ALDH1A1ALDH3A1ALDH2ACHECHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| CN-105237521-B | A kind of cumarin-isatin type compound and its preparation method and purposes | 诸暨市志缇生物科技有限公司 | 2018-08-24 | — | — | CN | disclosed |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2016-05-12 | — | — | US | disclosed |
| CN-105237521-A | Coumarin-isatin type compounds, and preparation method and purpose thereof | UNIV JISHOU | 2016-01-13 | — | — | CN | disclosed |
| US-9173886-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TRANA DISCOVERY, INC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2005-03-10 | — | — | US | disclosed |
| EP-1487792-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078394-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TYMP, MAVS, ZC3HAV1 | ALDH1A1 2506/4885ALDH3A1 1858/4885ALDH2 1751/4885 |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | ALDH1A1 2506/4885ALDH3A1 1858/4885ALDH2 1751/4885 |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TYMP, MAVS, ZC3HAV1 | ALDH1A1 2506/4885ALDH3A1 1858/4885ALDH2 1751/4885 |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | ALDH1A1 2506/4885ALDH3A1 1858/4885ALDH2 1751/4885 |
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | NR3C2, NR5A1, NR5A2 | ALDH1A1 723/4885ALDH3A1 820/4885ALDH2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.